Selskabets formål er at drive virksomhed med udvikling af lægemidler samt enhver i forbindelse hermed stående virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 3.5 mio. | -220 t. | 9.7 mio. | -2.3 mio. | 12 | |
CVR: 40169229
Secondary names: Zerion A/S
Previous names: Zerion ApS, Zerion Pharma ApS
Compared to 130 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Geelanie Rodriguez Briones joined the board
Lars Lykke Thomsen left the board
Geelanie Rodriguez Briones left the board
Companies in the same industry and area
CVR 37812730
CVR 39315769
CVR 41257547
CVR 41372079
CVR 44931478
Zerion Pharma A/S is currently facing significant financial challenges, with a negative profit trajectory and declining equity. In 2024, the company reported revenue of 3,452,016 DKK but incurred a loss of 220,020 DKK, following a substantial loss of over 11 million DKK in 2023. The equity position has deteriorated sharply, from -866,830 DKK in 2021 to -2,258,467 DKK in 2024, indicating increasing financial strain. While revenue has shown slight growth from 1.9 million DKK in 2021 to 3.5 million DKK in 2024, the persistent losses raise concerns about sustainability and operational efficiency in the competitive pharmaceutical manufacturing industry.
AI-generated summary
companydata.dk